Cigna Corporation Q2 FY2025 earnings call

David's remarks - Company has momentum and delivered differentiated financial results in Q2. Has three key differentiators: orientation toward anticipating and creating constructive disruption, diverse portfolio of businesses providing strategic flexibility, and relentless execution fueled by tenured team. Committed to better, like introducing AI-powered virtual assistant in Cigna Healthcare and partnering on prior authorization streamlining.

Brian's remarks - Cigna Healthcare financial results in line with expectations, medical care ratio 83.2% in Q2. Evernorth earnings slightly ahead of expectations, with strength in Specialty and Care Services and Pharmacy Benefit Services. Specialty and Care Services had 12% growth in normalized earnings, and there's growth opportunity in serving health systems and other providers with specialty services. Notable bright spots include solid Cigna Healthcare earnings, strong client retention in Evernorth Pharmacy Benefit Services, and innovation like GLP-1 benefit option.

Ann's remarks - Reviewed second quarter results, reaffirmed full year 2025 adjusted earnings per share outlook of at least $29.60. Discussed segment results, with Evernorth contributing over 60% of enterprise earnings, and Cigna Healthcare's consistent results in a challenging industry environment. Outlined full year 2025 outlook for growth platforms, including Evernorth and Cigna Healthcare, and capital management position.

In the second quarter, total revenue was $67.2 billion. For Evernorth, second quarter 2025 revenues grew to $57.8 billion, with pretax adjusted earnings reaching $1.7 billion. Specialty and Care Services within Evernorth demonstrated strong growth with revenue up 13% to $25.9 billion, and pretax adjusted earnings increased 12% year-over-year when normalizing for the absence of the VillageMD dividend. Pharmacy Benefit Services in Evernorth had pretax adjusted earnings increase to $833 million. For Cigna Healthcare, second quarter 2025 revenues were $10.8 billion, pretax adjusted earnings were $1.1 billion, and the medical care ratio was 83.2%. Cigna Healthcare's portfolio was strategically constructed for sustainable long-term growth in a dynamic environment, with its commercial business cost trends remaining elevated and the individual business utilization pressure manageable due to the smaller size of its ACA book.

Reaffirmed full year 2025 expectation for consolidated adjusted income from operations of at least $29.60 per share. For Evernorth, expects full year 2025 pretax adjusted earnings of at least $7.2 billion, with third quarter adjusted earnings for Evernorth expected to be slightly above 25% of the full year outlook. For Cigna Healthcare, outlook assumes elevated cost trends to persist throughout the year, expects full year 2025 pretax adjusted earnings of at least $4.125 billion, and third quarter adjusted earnings for Cigna Healthcare expected to be slightly below 25% of the full year outlook. Also expects full year medical care ratio within the range of 83.2% to 84.2%, with third quarter medical care ratio toward the upper end of the full year range reflecting typical seasonality.

Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from current expectations. A description of these risks and uncertainties is contained in the cautionary note to the earnings release and in recent reports filed with the SEC, including risks related to industry regulatory and legislative activity, technological, clinical and pharmacological advances, and other factors that could impact financial performance.

Q: A.J. Rice with UBS asked about the innovative products in Evernorth, particularly around GLP-1s, and how Cigna is using that in the commercial market and the advantage.

A: David mentioned the interdependency of pharmacy, medical, and mental health in the care equation, and Brian agreed that the 3 growth platforms are mutually reinforcing, with Evernorth's insight helping Cigna Healthcare manage financial performance.

Q: Lisa Gill with JPMorgan asked about the 2026 selling season and the Arkansas ruling and PBM legislation.

A: Brian talked about selling season themes like retention levels in pharmacy benefit services, market dynamics like affordability being top focus, and David commented on the Arkansas ruling, stating the court's TRO is positive as the legislation would arbitrarily constrain access, and emphasized the need for sustainable affordability improvements harnessing choice and innovation.

Q: Josh Raskin with Nephron Research asked about the exchange business on risk adjustment accruals and expectations for 2026.

A: Brian discussed the strategic choice to prioritize margin over growth in the individual exchange business, reducing customer base, and Ann mentioned a 2023 RADV adjustment and a modest positive adjustment to 2024 risk adjustment.

Q: Justin Lake with Wolfe Research asked about the impact of sophisticated hospital billing and coding on commercial trend, stop-loss, and employer ability to absorb rate increases.

A: David said there's elevated billing sophistication, Brian talked about stop-loss business growth and progress on margin profile improvement, and David noted affordability pressures on employers and the opening of innovative conversations.

Q: Charles Rhyee with TD Cowen asked about CuraScript in selling to health systems, contracting cycle, incumbents, and biosimilars.

A: Brian explained CuraScript's role in serving health systems, not competing with wholesalers in that space, and discussed biosimilars like STELARA and CuraScript's distribution of Quallent biosimilars.

Q: Kevin Fischbeck with Bank of America asked about competitive pricing environment in commercial and difference between subsegments.

A: Brian said the market is firm from a pricing standpoint, and Ann discussed margin dynamics with elevated cost trends and exceptions like the exchange business and stop-loss margin recovery.

Q: Jason Cassorla with Guggenheim asked about Evernorth margins in the quarter and margins in the specialty business.

A: Ann talked about margin drivers like client mix and drug mix in Evernorth Pharmacy Benefit Services, and Brian explained the margin paradigm for Evernorth's specialty business with distribution as low-margin and enablement services as fee-based with high margins.

Q: Erin Wright with Morgan Stanley asked about changes in retail reimbursement model and government business.

A: Brian said there's market curiosity around cost-plus models but limited appetite, and David amplified on the theme of increased affordability with performance-based models.

Q: Andrew Mok with Barclays asked about GLP-1 products and dispensing economics.

A: Brian discussed the GLP-1 innovations, including the new program with max out-of-pocket cost for patients, positive feedback, and that GLP-1 contributions to Evernorth in 2025 are in line with expectations.